Skip to main content
Premium Trial:

Request an Annual Quote

Serenex in Chemoproteomics Deal with GSK

NEW YORK, May 5 - Serenex said today that GlaxoSmithKline would use its chemoproteomics technology in select drug discovery programs.


GSK will have access to Serenex's Proteome Mining and Functional Proteome Fractionation technologies to screen GSK compounds against thousands of protein targets simultaneously.


According to Serenex, the companies will evaluate how these technologies impact the lead identification process.


Financial terms of the agreement were not provided.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.